The FDA is moving faster on psychedelics — now Washington must do more

The FDA has made significant strides in exploring psychedelics as potential treatments for mental health crises, especially suicide, which claims an American life every 11 minutes. This move follows President Trump’s executive order and suggests a promising new direction in mental health care. However, while the FDA's progress is crucial, it highlights the need for Washington to further support research and regulatory frameworks to ensure safe and effective use of these substances. The potential here is huge, but careful, comprehensive action is required to truly make an impact.